Table 1.

Patient demographics, pathology details, and clinical outcomes of patients donating tumor samples to this study

CohortTotalSunitinib naïveSunitinib treated
Number of patients462323
Age, median (IQR)a65.3 (59.0–72.9)67.5 (59.2–72.9)63.0 (56.0–73.0)
Male gendera30 (65.2%)14 (60.9%)16 (69.6%)
Fuhrman gradeb
 1000
 214 (30.4%)4 (17.4%)10 (43.5%)
 323 (50.0%)11 (47.8%)12 (52.2%)
 49 (19.6%)8 (34.8%)1 (4.3%)
Stagea
 T11 (2.2%)01 (4.3%)
 T26 (13.0%)2 (8.7%)4 (17.4%)
 T333 (71.7%)20 (87.0%)13 (56.5%)
 T46 (13.0%)1 (4.3%)5 (21.7%)
Gradec,d
 Single26 (57.8%)18 (81.8%)8 (34.8%)
 Multiple19 (42.2%)4 (18.2%)15 (65.2%)
Multiregion samplinga
 Protein44 (95.7%)22 (95.7%)22 (95.7%)
 RNA36 (78.3%)18 (78.3%)18 (78.3%)
 DNA42 (91.3%)21 (91.3%)21 (91.3%)
VHL statusa
 Mutation33 (71.7%)18 (78.3%)15 (65.2%)
 Wild-type13 (28.3%)5 (21.7%)8 (34.8%)
Number of metastatic sitesa
 122 (47.8%)14 (60.9%)8 (34.8%)
 218 (39.1%)7 (30.4%)11 (47.8%)
 36 (13.0%)2 (8.7%)4 (17.4%)
Heng classificationa
 Intermediate25 (54.3%)14 (60.9%)11 (47.8%)
 Poor19 (41.3%)7 (30.4%)12 (52.2%)
 Missing data2 (4.3%)2 (8.7%)0
1st line TKIeN/A12 (52.2%)N/A
Median overall survival, months (IQR)a15.9 (9.0–25.9)12.2 (6.7–19.4)23.0 (13.6–30.0)

NOTE: P values comparing sunitinib-naïve and sunitinib-treated patients.

Abbreviations: IQR, interquartile range; N/A, not applicable.

  • aP > 0.05.

  • bP = 0.02.

  • cP = 0.002.

  • dOne sunitinib-naïve patient had inadequate tissue for grade analysis, but enough tissue for multiregion sampling for RNA analysis only. Therefore, denominator is 45 samples in total, 22 for sunitinib-naïve patients, and 23 for sunitinib-treated patients.

  • eNumber of sunitinib-naïve patients who had post-nephrectomy TKIs.